N

Northwest Clinical Research Center | Bellevue, WA

Research site
(Unclaimed)
Location
1951 152nd Place NE 200, Bellevue, Washington, United States of America
Site insights

Top conditions

Depressive Disorder (52 trials)

Depression (50 trials)

Major Depressive Disorder (45 trials)

Migraine Disorders (38 trials)

Alzheimer Disease (19 trials)

Top treatments

Galcanezumab
Atogepant
SPD489
Rimegepant
Tanezumab
Rapastinel
LY3556050
Escitalopram
Hydrocodone Bitartrate
Troriluzole

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

48 of 222
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2)

The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of m...

Enrolling
Migraine
Drug: Lasmiditan

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).

Enrolling
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

This study will evaluate the Long-Term Safety and Tolerability of Atogepant 60 mg daily for the Prevention of Migraine in Participants with Chronic o...

Active, not recruiting
Chronic Migraine
Episodic Migraine
Drug: Atogepant 60 mg

The purpose of the chronic pain master protocol is to compare independent pain interventions and establish an overarching structure for the disease-s...

Enrolling
Chronic Low-back Pain
Diabetic Neuropathic Pain
Drug: LY3526318 ISA
Drug: LY3857210 ISA

The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving dep...

Enrolling
Depressive Disorder, Major
Anhedonia
Drug: Aticaprant
Other: Placebo

The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepres...

Enrolling
Depressive Disorder, Major
Drug: Aticaprant

This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptom...

Enrolling
Alzheimer's Disease
Mental Disorders
Drug: Donanemab
Drug: Placebo

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participant...

Enrolling
Chronic Migraine
Drug: Galcanezumab
Drug: Placebo

The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatme...

Enrolling
Episodic Migraine
Drug: Placebo
Drug: Galcanezumab

The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabet...

Enrolling
Obesity
Type 2 Diabetes
Drug: Tirzepatide
Drug: Placebo

The purpose of this study is to evaluate the efficacy of JNJ-55308942 compared to placebo on symptoms of depression in participants with bipolar diso...

Enrolling
Bipolar Disorder
Drug: JNJ-55308942
Drug: Placebo

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks an...

Enrolling
Migraine
Drug: Placebo
Drug: Lasmiditan

The main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropath...

Enrolling
Diabetic Peripheral Neuropathy
Drug: Placebo
Drug: LY3556050

The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early Alzheimer's d...

Enrolling
Alzheimer's Disease
Drug: Remternetug (SC)
Drug: Placebo

The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master pr...

Enrolling
Overweight
Knee Pain Chronic
Drug: Retatrutide
Drug: Placebo

The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have o...

Enrolling
Overweight
Obesity
Drug: Placebo
Drug: Retatrutide

The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or are overweight a...

Enrolling
Overweight
Obesity
Drug: Placebo
Drug: Retatrutide

The main purpose of this study is to determine if combining tirzepatide with the mibavademab will result in more weight loss in adult participants th...

Begins enrollment this month
Obesity
Drug: Mibavademab-Placebo
Drug: Mibavademab

This is a Phase 3, 6-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with schizophrenia with an inadequ...

Enrolling
Schizophrenia
Drug: Placebo
Drug: Xanomeline and Trospium Chloride Capsules

Trial sponsors

Lilly logo

Lilly (41 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems